CSL Share Price
View CSL's share price performance over a 12 month period.
Latest Financial ReportsCSL Profile on ASX website
Computershare's Investor Centre website
Financial Calendar 2015
11 Feb -
Half Year Results
12 Aug -
Full Year Results
15 Oct -
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
About the CSL Group
CSL Limited News
CSL Behring News
Head of Investor Relations
Phone: +613 9389 2818
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email
CSL Limited has over 10,000 staff in more than 20 countries. We produce many life-saving and life-enhancing medicines that enable thousands of people around the world to lead normal healthy lives. Our headquarters is in Australia and we have substantial manufacturing operations in the US, Germany and Switzerland.
CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent a range of human medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself.
New €350 Million Private Placement
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 12 November 2014 it closed a new €350 million private placement in the U.S. The private placement was foreshadowed in CSL’s full year announcement in August 2014.
Full Year Results announcement for 2013/14
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,307 million for the full year ended 30 June 2014, up US$96 million or 8% on a reported basis when compared to the prior comparable period (PCP). The result includes
a one-off U.S. antitrust class action litigation settlement. Earnings per share (EPS) grew 11%, benefiting from current and past capital management initiatives.
Half Year Results announcement for 2013/14
CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$646 million for the six months ended 31 December 2013, up US$21 million or 3% on a reported basis when compared to the prior comparable period (PCP). The result included a one-off U.S. antitrust class action litigation settlement of US$64 million, or US$39 million after tax.
Prior ASX Releases
View the ASX Archive